Back to Journals » ClinicoEconomics and Outcomes Research » Volume 7

Linezolid for the treatment of hospital-acquired pneumonia in a Chinese tertiary hospital

Authors Lesher B, Liu Z, Chen Y, Gao X

Received 29 May 2015

Accepted for publication 3 June 2015

Published 9 October 2015 Volume 2015:7 Pages 521—526


Checked for plagiarism Yes

Editor who approved publication: Dr Giorgio Colombo

Beth A Lesher,1 Zhengyin Liu,2 Yixi Chen,3 Xin Gao1

1Pharmerit International, Bethesda, MD, USA; 2Department of Infectious Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 3Pfizer Investment Co, Ltd, Beijing, People’s Republic of China

We read with interest the study published by Song et al describing their retrospective analysis of the clinical response and hospital costs associated with the empiric use of vancomycin or linezolid therapy in patients with hospital-acquired pneumonia (HAP) in the People’s Republic of China.1 Results from matched comparisons showed similar clinical response (30.0% vs 31.7%; P=0.847) and treatment failure rates (55.0% vs 45.0%; P=0.289) but a significantly lower in-hospital mortality rate (3.3 vs 18.3%; P=0.013) for vancomycin-treated patients compared to linezolid-treated patients. Treatment failure rates (odds ratio [OR], 1.139; P=0.308) and risk of in-hospital mortality were comparable (OR, 0.186; P=0.055) between vancomycin- and linezolid-treated patients following further adjustment for an imbalance in variables between the matched treatment groups. Reported total hospital costs were not significantly different between vancomycin- (RMB 113,160) and linezolid (RMB 133,825)-treated patients (P=0.076).

View original paper by Song et al

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Readers of this article also read:

Arsenic sulfide inhibits cell migration and invasion of gastric cancer in vitro and in vivo

Zhang L, Kim S, Ding W, Tong Y, Zhang X, Pan M, Chen S

Drug Design, Development and Therapy 2015, 9:5579-5590

Published Date: 9 October 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010